GABRD promotes progression and predicts poor prognosis in colorectal cancer

Gengming Niu(Institute for Biomedicine), Chongwei Ke(Fudan University), He Meng(Shanghai Jiao Tong University), Shanliang Han(Fudan University), Runqi Hong(Fudan University), Xiaotian Zhang(Peking University), Ke Xu(Shanghai Jiao Tong University), Li Deng(Capital Medical University), Zhiqing Hu(Central South University)

Open Medicine

January 1, 2020

10.1515/med-2020-0128

Cited by 42

Related Papers

Light‐Triggered Theranostics Based on Photosensitizer‐Conjugated Carbon Dots for Simultaneous Enhanced‐Fluorescence Imaging and Photodynamic Therapy

|Advanced Materials|2012|696

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

|The Lancet Oncology|2021|436

A Novel Inflammation and Insulin Resistance Related Indicator to Predict the Survival of Patients With Cancer

|Frontiers in Endocrinology|2022|161

Single‐cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer

|Immunology|2022|136

<i>In vivo</i> MR and Fluorescence Dual-modality Imaging of Atherosclerosis Characteristics in Mice Using Profilin-1 Targeted Magnetic Nanoparticles

|Theranostics|2015|110